Reversible acylation of factor Xa as a potential therapy for hemophilia

Thrombosis Research

Volumn 88, Issue 4, 1997, Pages 365-372

  Lin, Pei Hua ^a   Laibelman, Alan M ^a   Sinha, Uma ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Acyl enzyme; Factor Xa; Hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A;

ACYLATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG FORMULATION; HEMOPHILIA; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL;

ACYLATION; ANIMALS; BENZOATES; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FACTOR XA; HEMOPHILIA A; HUMANS; INDICATORS AND REAGENTS; KINETICS; THROMBOPLASTIN;

EID: 0343134389     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00267-3     Document Type: Article

References (16)

1. Goldsmith JC The challenges of inhibitor patient care. Sem Hematol. 30:1993;1-2.
2. Wolf DL, Lin PH, Hollenbach S, Wong A, Phillips DR, Sinha U. Procoagulant activity of reversibly acylated human factor Xa. Blood 1995;86:4153-7.
3. Wolf DL, Sinha U, Hancock TE, Lin PH, Messier TL, Esmon CT, Church WR. Design of constructs for the expression of biologically active recombinant human factors X and Xa. J Biol Chem 1991;266:13726-30.
4. Sinha U, Hancock TE, Nzerem JJ, Lin PH, Tomlinson JE, Wolf DL. Effect of gamma carboxylation on prothrombinase inhibitory activity of catalytically inactive factor Xa. Thromb Res 1994;75:427-36.
5. Pratt CW, Monroe DM. Microplate coagulation assays. Bio Techniques 1992;13:430-3.
6. Smith RAG, Garman AJ, Morgan GS. Structure-activity relationships for the formation and breakdown of acylated fibrinolytic enzymes. In: Davidson JF, Donati MB, Coccheri S, editors. Progress in Fibrinolysis. Vol VII. Churchill Livingstone; 1985.
7. Fife TH, Milstien JB. Steric effects in the deacylation of acyl-chymotrypsins. Biochemistry 1967;6:2901-7.
8. Faller LO, Sturtevant JM. The kinetics of the alpha-chymotrypsin catalyzed hydrolysis of p-nitrophenyl acetate in organic solvent-water mixtures. J Biol Chem 1966;241:4825-34.
9. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: A new approach to thrombolytic therapy. Nature 1981;290:505-8.
10. White GC, Roberts HR The treatment of Factor VIII inhibitors - a general overview. Vox Sanguinis. 70:1996;19-23.
11. Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rVIIa): Results of a phase I study. Blood Coagul Fibrinolysis 1993;4:521-7.
12. Warrier I, Lusher JM Recombinant (r) factor VIIa (NovoSeven) is the most appropriate treatment for children with hemophilia B complicated by inhibitor antibodies and anaphylaxis to fIX containing products (abstract). Blood. 88:1996;1756.
13. Hay C, Lozier JN. Porcine factor VIII therapy in patients with factor VIII inhibitors. In: Alderot LM, editor. Inhibitors to Coagulation Factors. Plenum Press; 1995.
14. Ni HY, Giles AR. Normalization of the haemostatis plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles. Thromb Haemost 1992;67:264-71.
15. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1990;265:1688-92.
16. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy for hemophilia B: Sustained partial correction in factor IX deficient dogs. Science 1993;262:117-9.